Paid speaking “is perfectly legal, and if people want to work for drug companies, this is America,” said Scully, whose specialty has often been criticized for its over-reliance on medications. “But everybody needs to be clear — this is marketing.”
The government gives psychiatry its fake legitimacy. That’s how the game works. The government blesses the medical licensing boards that award psychiatrists permission to drug your children, alter their brains, poison them, and of course make all the fake diagnoses in the first place. Without the government, these fakes would sink into the waves and be gone forever. Nobody in his right mind or wrong mind would ever step into a psychiatrist’s office. It would be like volunteering to stumble out on to a mine field seeded with explosives.
Media, naturally, go along with the psychiatric hoax. Thousands of articles keep coming out of the hopper to support the authoritative pronouncements of these deranged monsters with medical degrees and “training” in diagnosing mental illnesses.
There are no mental illnesses or disorders. There never have been.
In 1952, the Diagnostic and Statistical Manual of Mental Disorders – the DSM – psychiatrist’s bible for diagnosis of mental problems, was a 132-page booklet. Today, in its fourth incarnation, it is a 886-page doorstop. Controversy is now swirling over the fifth instalment, slated for publication in May 2013.
It seems that every DSM upgrade contains more and more “disorders” that are open to question for their vagueness and open-endedness.
Because psychiatric diagnoses are based on the subjective interpretation of behaviour by third parties. A psychiatrist may be highly trained but their diagnosis is still subjective.
How often do they get it wrong? Unlike in most other areas of medicine, where misdiagnosis is taken seriously, nobody knows very much about the extent of it in psychiatry. It has been very poorly studied.
Johnson & Johnson, the company that makes the antipsychotic drug Risperdal, has tentatively agreed to a settlement of $2.2 billion to resolve a federal investigation into the company’s marketing practices.